Elagolix and Relugolix Prior Authorization with Quantity Limit Program Summary
Customize your policy alerts
Sign up for all prime_therapeutics policy alerts
Know when prime_therapeutics releases new policies or updates existing guidance.
Monitor payer policy activity
This commercial Boeing policy governs prior authorization and quantity limits for Orilissa, Oriahnn, and Myfembree. Coverage applies to eligible premenopausal patients receiving therapy for endometriosis-associated pain or heavy menstrual bleeding associated with uterine fibroids, subject to clinical criteria, contraindication review, duration limits, and product-specific quantity limits.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.